Work

Interaction of novel imidazolium-based ionic liquids with cholinesterases: an in vitro and in silico evaluation

Year: 2026
Type: article
Abstract: The increasing demand for efficient and sustainable CO 2 capture technologies has driven the development of new ionic liquids (ILs) as potential alternatives to established sorbents. However, before large-scale industrial adoption, a comprehensive understanding of the toxicological profiles of these new ILs is essential to ensure human and environmental safety. Thus, in this study, we conducted a toxicological screening of nine imidazolium-based ILs (five previously reported, IL-1–IL-5, and four newly synthesized analogs, IL-6–IL-9), focusing on their inhibitory effects on the activity of human cholinesterase enzymes (acetylcholinesterase, AChE, and butyrylcholinesterase, BuChE). Initial screening at 40 µM revealed that, among the nine ILs, only IL 1-Dodecyl-3-methyl-2-(4-hydroxyphenyl) imidazolium iodide (IL-9), the dodecyl-substituted analog, inhibited human erythrocyte AChE (IC 50 = 3.64 µM) and plasma BuChE (IC 50 = 0.87 µM). When compared with compounds edrophonium and sodium dodecyl sulfate (SDS), only edrophonium inhibited AChE activity (IC 50 = 3.03 µM), and neither edrophonium nor SDS inhibited BuChE considerably. Molecular docking simulations suggested that the long alkyl moiety of IL-9 stabilizes its interaction near the catalytic active site (CAS) and peripheral anionic subsite (PAS) of both AChE and BuChE. While shorter-chain ILs demonstrated no inhibitory effect, the cholinesterase inhibition exhibited by IL-9 indicates that elongating the alkyl chain intr​oduces significant neurotoxic risks. Consequently, future designs of imidazolium-based CO 2 sorbents must carefully balance these structural modifications to ensure environmental and occupational safety.
Source: Ionics
Language: English
Field: Chemistry
Open Access status: hybrid
Estimated APC paid: $3,590
OpenAlex ID: W7162337442
FWCI:
Cites: 65
Cited by:
Related to: 10